Biomarin Pharmaceuticals (BMRN)

$58.58 +0.51 (0.88%)
Market Cap 11.25B
Revenue (ttm) 2.85B
Net Income (ttm) 426.86M
EPS (ttm) N/A
PE Ratio 15.74
Forward PE 15.68
Profit Margin 14.96%
Debt to Equity Ratio 0.00
Volume 1,654,800
Avg Vol 2,197,710
Day's Range N/A - N/A
Shares Out 192.02M
Stochastic %K 81%
Beta 0.18
Analysts Strong Sell
Price Target $97.42

Company Profile

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic pep...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 506 6700
Address:
770 Lindaro Street, San Rafael, United States
DukeofDividends
DukeofDividends Aug. 23 at 7:44 AM
$BMRN BioMarin Pharmaceutical Inc has rare disease drugs but faces pipeline execution risk
0 · Reply
TPTradingCo
TPTradingCo Aug. 22 at 5:42 PM
$BMRN fittin’ to rip…
0 · Reply
NervyBiotechs
NervyBiotechs Aug. 22 at 1:38 PM
$BMRN Can't find any evidence of this online. Have you a source please?
0 · Reply
CDMO
CDMO Aug. 21 at 6:54 PM
$BMRN very close to just take the loss and move on. But i will stick around probably
0 · Reply
scienceleads
scienceleads Aug. 21 at 4:11 PM
$BMRN a move above 70 is key.
0 · Reply
tradeitbetit
tradeitbetit Aug. 21 at 3:45 PM
$BMRN rotation to safe heaven in the horizon. A quick search will show this diamond is one of the best value stocks out there… holding
0 · Reply
GueroMoonshot
GueroMoonshot Aug. 21 at 1:28 AM
$BMRN think their hemophilia franchise could be considered for big pharma topline growth?
1 · Reply
jerchess
jerchess Aug. 19 at 9:23 PM
$BMRN very nice chart with strong support just underwear it’s trading at.
0 · Reply
jerchess
jerchess Aug. 19 at 9:03 PM
$BMRN not a mistake https://www.youtube.com/live/48iF8YR2GKk?si=e4lXiOtaxQblQxxj
0 · Reply
tradeitbetit
tradeitbetit Aug. 19 at 2:59 PM
$BMRN so mad at myself for choosing this turd instead of $NVO 😖😖😖
1 · Reply
Latest News on BMRN
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401

Aug 5, 2025, 4:20 PM EDT - 19 days ago

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401

INZY

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

Aug 5, 2025, 1:11 PM EDT - 19 days ago

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 11:04 PM EDT - 20 days ago

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

Aug 4, 2025, 4:02 PM EDT - 20 days ago

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

Aug 1, 2025, 9:00 AM EDT - 23 days ago

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

Jul 22, 2025, 9:00 AM EDT - 4 weeks ago

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 6 weeks ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BBIO GILD INSM XBI

BioMarin Announces Completion of Acquisition of Inozyme

Jul 1, 2025, 8:45 AM EDT - 7 weeks ago

BioMarin Announces Completion of Acquisition of Inozyme

INZY

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

Jun 24, 2025, 9:00 AM EDT - 2 months ago

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

May 21, 2025, 5:56 PM EDT - 3 months ago

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

INZY

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

May 16, 2025, 7:30 AM EDT - 3 months ago

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

INZY

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

May 12, 2025, 9:05 AM EDT - 3 months ago

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:25 PM EDT - 4 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

May 1, 2025, 4:05 PM EDT - 4 months ago

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

Apr 17, 2025, 9:00 AM EDT - 4 months ago

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion

Apr 3, 2025, 3:37 PM EDT - 5 months ago

BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

Apr 2, 2025, 9:00 AM EDT - 5 months ago

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Mar 20, 2025, 9:00 AM EDT - 5 months ago

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

Feb 25, 2025, 9:00 AM EST - 6 months ago

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

Feb 24, 2025, 4:05 PM EST - 6 months ago

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

Why Is BioMarin Stock Trading Higher On Thursday?

Feb 20, 2025, 9:39 AM EST - 6 months ago

Why Is BioMarin Stock Trading Higher On Thursday?

BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 8:08 PM EST - 6 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

Feb 19, 2025, 4:05 PM EST - 6 months ago

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

Feb 5, 2025, 9:00 AM EST - 7 months ago

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

Jan 23, 2025, 10:42 AM EST - 7 months ago

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

Jan 13, 2025, 12:00 PM EST - 7 months ago

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

Jan 6, 2025, 8:30 AM EST - 8 months ago

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

Nov 21, 2024, 3:00 PM EST - 9 months ago

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

Nov 16, 2024, 10:45 AM EST - 10 months ago

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

BioMarin to Participate in Three Upcoming Investor Conferences

Nov 6, 2024, 8:00 AM EST - 10 months ago

BioMarin to Participate in Three Upcoming Investor Conferences

BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 8:26 PM EDT - 10 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

Oct 29, 2024, 4:03 PM EDT - 10 months ago

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

Oct 16, 2024, 8:30 AM EDT - 11 months ago

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

3 Oversold Stocks with Big RSI Rebound Potential

Oct 8, 2024, 2:42 PM EDT - 11 months ago

3 Oversold Stocks with Big RSI Rebound Potential

ELV HUM

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

Sep 25, 2024, 3:50 PM EDT - 11 months ago

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

Sep 18, 2024, 8:00 AM EDT - 1 year ago

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

Ascendis Challenges BioMarin, But Market Response Seems Excessive

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Ascendis Challenges BioMarin, But Market Response Seems Excessive

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

Sep 4, 2024, 1:00 PM EDT - 1 year ago

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

Sep 4, 2024, 7:30 AM EDT - 1 year ago

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

Aug 29, 2024, 8:00 AM EDT - 1 year ago

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

BioMarin to reduce global workforce by about 225 employees

Aug 28, 2024, 5:32 PM EDT - 1 year ago

BioMarin to reduce global workforce by about 225 employees

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

Aug 21, 2024, 4:21 PM EDT - 1 year ago

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

BioMarin Announces New R&D and Business Development Leadership

Aug 21, 2024, 8:30 AM EDT - 1 year ago

BioMarin Announces New R&D and Business Development Leadership

BioMarin to Host 2024 Investor Day on September 4th in New York

Aug 19, 2024, 9:00 AM EDT - 1 year ago

BioMarin to Host 2024 Investor Day on September 4th in New York

Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance

Aug 6, 2024, 3:06 PM EDT - 1 year ago

Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance

BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 9:35 PM EDT - 1 year ago

BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript

BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance

Aug 5, 2024, 4:03 PM EDT - 1 year ago

BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance

BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy

Aug 5, 2024, 4:01 PM EDT - 1 year ago

BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

Jul 24, 2024, 4:05 PM EDT - 1 year ago

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET

Jul 23, 2024, 8:00 AM EDT - 1 year ago

BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET

DukeofDividends
DukeofDividends Aug. 23 at 7:44 AM
$BMRN BioMarin Pharmaceutical Inc has rare disease drugs but faces pipeline execution risk
0 · Reply
TPTradingCo
TPTradingCo Aug. 22 at 5:42 PM
$BMRN fittin’ to rip…
0 · Reply
NervyBiotechs
NervyBiotechs Aug. 22 at 1:38 PM
$BMRN Can't find any evidence of this online. Have you a source please?
0 · Reply
CDMO
CDMO Aug. 21 at 6:54 PM
$BMRN very close to just take the loss and move on. But i will stick around probably
0 · Reply
scienceleads
scienceleads Aug. 21 at 4:11 PM
$BMRN a move above 70 is key.
0 · Reply
tradeitbetit
tradeitbetit Aug. 21 at 3:45 PM
$BMRN rotation to safe heaven in the horizon. A quick search will show this diamond is one of the best value stocks out there… holding
0 · Reply
GueroMoonshot
GueroMoonshot Aug. 21 at 1:28 AM
$BMRN think their hemophilia franchise could be considered for big pharma topline growth?
1 · Reply
jerchess
jerchess Aug. 19 at 9:23 PM
$BMRN very nice chart with strong support just underwear it’s trading at.
0 · Reply
jerchess
jerchess Aug. 19 at 9:03 PM
$BMRN not a mistake https://www.youtube.com/live/48iF8YR2GKk?si=e4lXiOtaxQblQxxj
0 · Reply
tradeitbetit
tradeitbetit Aug. 19 at 2:59 PM
$BMRN so mad at myself for choosing this turd instead of $NVO 😖😖😖
1 · Reply
Pobr
Pobr Aug. 19 at 1:41 PM
$BMRN 95 $ soon...
1 · Reply
ROME_IS_BURNING
ROME_IS_BURNING Aug. 15 at 7:13 PM
$BMRN 2027 $100 calls... Just saying. For 80 bucks, if this COMES remotely close to 100; $$$$$
0 · Reply
rlane72
rlane72 Aug. 15 at 12:16 PM
$BMRN I told yall to wait, you so fkn impatient, now you gonna hate yourself for not listening.
0 · Reply
Biotechace
Biotechace Aug. 15 at 4:14 AM
$BMRN $9.55 2030 earnings projection. 15 PE would put this around $140.
0 · Reply
CDMO
CDMO Aug. 13 at 6:58 PM
$BMRN such a looser stock
0 · Reply
tradeitbetit
tradeitbetit Aug. 12 at 6:25 PM
$BMRN they dont even care anymore, seems like clear manipulation so the institutions can pocket all those premiums for Aug 15 calls above 57… WOW thats a lotta money
0 · Reply
Pobr
Pobr Aug. 12 at 1:56 PM
$BMRN
0 · Reply
svk33
svk33 Aug. 11 at 4:48 PM
$BMRN Sooo that lil pump was just a lower high for now. Gods of patience, please give me strength watch out for 54's again. that Sob better Hold!
0 · Reply
ripster47
ripster47 Aug. 11 at 2:56 PM
$BTCUSD 🚨 Nice bounce from Ripster 1 HR MTF Yes, Ripster MTF clouds works on crypto too!!! Ethereum is squeezing Helping $COIN $BMRN but market $SPY $QQQ not helping
0 · Reply
ROME_IS_BURNING
ROME_IS_BURNING Aug. 10 at 9:44 PM
$BMRN then short it! I DARE YOU!
1 · Reply
welcome2themachine
welcome2themachine Aug. 8 at 11:04 PM
$BMRN ouch. Triple bottom broken on this.
0 · Reply
ROME_IS_BURNING
ROME_IS_BURNING Aug. 8 at 9:17 PM
$BMRN I still think 27 $100 leaps are the way to play. Most upside w/o paying a ton of premimum.
2 · Reply